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m-Tetra(hydroxyphenyl)chlorin (m-THPC, Foscan, Temoporfin) has an unusually high photodynamic efficacy which cannot be
explained by its photochemical properties alone. In vivo interactions are therefore of critical importance in determining this high
potency. The pharmacokinetics of m-THPC in a rat tumour model was determined using
14C m-THPC in an LSBD1 fibrosarcoma
implanted into BDIX rats. The photodynamic therapy (PDT) efficacy was determined at different drug administrations to light
intervals and correlated with the tumour and plasma pharmacokinetic data. The plasma pharmacokinetics of m-THPC can be
interpreted by compartmental analysis as having three half-lives of 0.46, 6.91 and 82.5h, with a small initial volume of distribution,
suggesting retention in the vascular compartment. Tissues of the reticuloendothelial system showed high accumulation of m-THPC,
particularly the liver. PDT efficacy of m-THPC over the same time course seemed to exhibit two peaks of activity (2 and 24h), in
terms of tumour growth delay with the peak at 24h postinjection correlating to the maximum tumour concentration. Investigation on
tumour cells isolated from m-THPC-treated tumours suggested that the peak PDT activity at 2h represents an effect on the
vasculature while the peak at 24h shows a more direct response. These results indicate that the in vivo PDT effect of m-THPC occurs
via several mechanisms.
British Journal of Cancer (2003) 89, 398–404. doi:10.1038/sj.bjc.6601101 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: Foscan; m-THPC; temoporfin; photodynamic therapy; pharmacokinetics
                                           
Photodynamic therapy (PDT) is becoming accepted as an
alternative to conventional cancer treatments for certain indica-
tions and other nononcological conditions. It is based on a tumour
accumulation of a photosensitiser, which, when activated by light,
results in tumour destruction via reactive oxygen species (Ochsner,
1997). The selectivity of PDT relies upon the targeting of the light
delivery in combination with the accumulation/retention of the
photosensitiser in malignant tissue. The time interval between
photosensitiser administration and light delivery is crucial for the
optimal clinical efficacy of PDT. The distribution of the photo-
sensitiser both in the tumour as a whole and throughout the
tumour compartments is dependent on this interval as well as in
vivo interactions that affect photosensitiser aggregation, delivery
and uptake (Boyle and Dolphin, 1996).
m-Tetra (hydroxyphenyl)chlorin (m-THPC), a second-genera-
tion photosensitiser, has already been shown to be more potent
than Photofrin (PII). It has been suggested that it is up to 200 times
more powerful (Van Geel et al, 1995; Ball et al, 1999). This figure
takes into account the drug dose required (0.15mgkg
 1 compared
to 10mgkg
 1 for PII) and the lower light doses necessary
(30Jcm
 1 rather than 150Jcm
 1) to produce similar PDT results.
However, the reason for this effectiveness remains unresolved even
considering the advantageous photoproperties of increased molar
absorption coefficient and a favourable shift in the wavelength
maximum (652nm rather than 630nm) (Bonnett et al, 1989).
Preclinical studies have already shown the importance of the
drug to light interval in m-THPC PDT (Ris et al, 1991). The longer
time intervals are preferable to optimise PDT treatment by limiting
normal tissue damage. Another consideration with m-THPC is the
unusual human plasma pharmacokinetics. After an intravenous
injection, the plasma level initially falls exponentially but at
approximately 10h it begins to rise to a secondary peak at 24h
(Ronn et al, 1996; Glanzmann et al, 1998). This may change the
level of m-THPC in the tumour vasculature and the rate of uptake
of m-THPC in the tumour giving different PDT responses. In
addition, m-THPC initially forms an aggregated complex in human
plasma that slowly redistributes to the lipoproteins where it is
predominantly monomeric. These different aggregation states of
the photosensitiser would alter its tumour uptake and localisation
(Hopkinson et al, 1999).
To help unravel the in vivo interactions of m-THPC, the PDT
effect needs to be correlated with drug level and tumour
localisation. In this study, we have used a
14C radiolabelled
preparation of m-THPC to investigate the pharmacokinetics of the
sensitiser in male BDIX rats implanted with a subcutaneous LSBD1
fibrosarcoma. The same time course was then used to assess PDT
efficacy using tumour growth delay as the end point. The main aim
of this study was to correlate tumour and tissue concentrations
with PDT response.
To study the mechanism of action of m-THPC, the effects of
irradiation on tumour cells isolated from m-THPC-containing
tumours were compared to the effects of the tumour in vivo.
MATERIALS AND METHODS
m-Tetra (hydroxyphenyl)chlorin and
14C m-THPC were sup-
plied by Scotia QuantaNova. The sensitiser was dissolved as Received 19 February 2003; revised 30 April 2003; accepted 2 May 2003
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srecommended for intravenous injection in a mixture of poly-
ethylene glycol 400:ethanol:water (3:2:5 by volume). Radio-
active sensitiser was diluted with unlabelled m-THPC to a specific
activity of 16.9mCimmol
 1 and a final concentration of
0.6mgml
 1. Unlabelled m-THPC was also prepared as a
0.6mgml
 1 solution and the solutions were stored in 0.5ml
aliquots at  201C.
Animal and tumour model
Animal experiments were performed under protocols approved by
the local experimental animal welfare committee and conformed to
National and European regulations for animal experimentation.
Experiments were covered by Home Office premises, project and
personal licenses as well as keeping within the UKCCCR guidelines
on use of animals for experimental neoplasia (Workman et al,
1998).
Male BDIX rats were used at 12–13 weeks old and weighed
approximately 300–400g. The tumour model used was a poorly
differentiated fibrosarcoma (LSBD1), which grows as a sphere
causing no skin ulceration and no attachment to the muscle below.
The tumour was implanted as a subcutaneous fragment (1mm)
when the rats weighed 300–400g (Gilson et al, 1990).
Tumour measurement and administration of m-THPC
Rats were weighed and tumours measured daily. Measurements
were taken on three perpendicular axes using callipers to calculate
the mean tumour diameter. When tumours had reached a mean
diameter of 8–10mm, approximately 10 days after implantation,
they were suitable for PDT treatment and were entered into the
study. m-Tetra (hydroxyphenyl)chlorin (0.3mgkg
 1) was injected
intravenously via the penile vein.
14C m-THPC or unlabelled m-THPC was administered at 0, 2, 4,
6, 18, 24, 48, 72 or 96h before the tumour was predicted to reach
8–10mm in diameter. This was determined from the known
tumour growth kinetics. In addition, a 168-h time point was used
in the pharmacokinetic study that had a slightly different protocol,
consisting of m-THPC administration when the tumour was 8–
10mm. All procedures were carried out using UKCCCR guidelines
(Workman et al, 1998).
Pharmacokinetic study
After the predetermined times, the animals were killed by deep
anaesthesia with ether, followed by cervical dislocation. The tissues
selected for dissection were tumour, liver, heart, kidney, lung,
muscle (skeletal muscle of the hind leg) and skin (right abdominal
wall). Dissection was carried out under subdued light, and all
tissues were washed in isotonic saline and blotted dry. Triplicate
samples of each tissue (90–110mg) were weighed directly into
scintillation vials. Blood samples (2.5ml) were collected by heart
puncture (immediately after cervical dislocation). The samples
were then diluted with an equal volume of heparin solution
(10Uml
 1) and centrifuged to separate the plasma. Three animals
were used per time point and all samples were stored at  201C.
Procedures were carried out using UKCCCR guidelines (Workman
et al, 1998).
Each tissue sample was digested by addition of 1ml of 1 M
sodium hydroxide to the scintillation vial and shaking overnight in
the dark at 401C. Scintillation fluid (10ml) (Ultima Gold, Perkin
Elmer Life Sciences, Cambridge, U.K.) were added to each vial
followed by vigorous shaking. Radioactivity was determined using
a Packard Liquid Scintillation Analyzer (1900TR). An internal
radiolabelled standard,
14C n-hexadecane was used to determine
the counting efficiency. The plasma samples were analysed using
200ml aliquots (in triplicate for each animal) mixed with 10ml
scintillation fluid and counted as above.
For each animal, the mean tissue concentration was calculated.
The mean and the standard deviation (s.d.) for all three animals at
each time point were calculated. The plasma pharmacokinetics was
analysed by compartmental and noncompartmental mathematical
methods (Yamaoka et al, 1978; Clark and Smith, 1986).
Photodynamic therapy on the LSBD1 tumour
Tumours were irradiated interstitially using a 200mm optical fibre
with a 0.5cm diffusing tip (Feather et al, 1989). A light dose of 50J
was delivered at 100mW from a 652nm diode laser (Diomed Inc.,
Boston, USA). During treatment, rats were placed on a heated mat
and kept anaesthetised using a halothane inhalation system.
Tumour growth delays were calculated by subtracting the time
taken for control animals to reach a mean tumour diameter of
15mm, from the time taken for treated tumours to reach 15mm.
This end point was used to assess the response to the PDT
treatment and used for comparison between time points (Thom-
linson and Craddock, 1967).
Photodynamic therapy on isolated LSBD1 tumour cells
The LSBD1 tumour was implanted subcutaneously in the BDIX
male rat. When the tumours reached a diameter of 8–10mm, m-
THPC was administered intravenously at a dose of 0.3mgkg
 1
(0.6mgml
 1 solution) and the animals were killed at 2 and 24h
together with a control animal. Procedures were carried out using
UKCCCR guidelines (Workman et al, 1998). The tumour was
excised (intact) under aseptic conditions and subdued lighting and
was cut into quarters on a sterile Petri dish. The white tumour
tissue was removed from the outer tumour capsule. The tumour
was shredded using two scalpels and incubated with 10ml of 0.25%
collagenase II solution containing 1% BSA (added just before
incubation) for 1–2h at 371C, shaking intermittently.
The tumour cell suspension was passed through a 150 mm nylon
filter mesh and the cells collected by centrifugation (MSE Mistral
2000, 500g, 5min). The collagenase II mixture was poured off and
the remaining cells resuspended in 10ml of phosphate-buffered
saline (PBS). The cell suspension was then passed through a
100mm nylon filter mesh and centrifuged as above. The cells were
again resuspended in 10ml of PBS and centrifuged. This was
repeated until the suspension was clear, then the cells were
suspended in 5ml Dubecco’s modified Eagle’s medium (DMEM)
containing 10% FCS and 1% glutamine. The concentration of cells
in the suspension was determined using a haemocytometer. Cells
were seeded at 1 10
5 per well of a 96-well plate, in 200mlo f
medium, and left for 4h to allow cell attachment. Immediately
before illumination, the medium was removed from the cells and
replaced with PBS.
The plates were irradiated using a xenon arc lamp fitted with a
652nm filter (715nm). The cells were treated with light doses of
0, 2.5, 5, 10, 20 and 40Jcm
 2, by varying the illumination time (0–
16min) and then incubated for 18–24h at 371C before determin-
ing cell survival by the MTT assay (Mosmann, 1983).
Statistical analysis
Statistical analysis was carried out using analysis of variance in the
computer program SAS 6.12 system for Windowst (SAS Institute
Inc., SAS Campus Drive, NC, USA).
RESULTS
Plasma pharmacokinetics of m-THPC in the BDIX rat
Figure 1 shows the levels of m-THPC in rat plasma at various times
after administration (0. 3mgkg
 1). The plasma levels were initially
high (9.37mgml
 1) and appear to declined exponentially as would
PDT effects of m-THPC
HJ Jones et al
399
British Journal of Cancer (2003) 89(2), 398–404 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
snormally be expected for an intravenous injection. The clearance
from plasma, however, did not follow a simple monoexponential
decay but could be fitted to multiple exponentials, and because of
this the data were analysed by both a noncompartmental and a
compartmental approach (Yamaoko et al, 1978; Clark and Smith,
1986). With a compartmental approach, the data best fit a three
exponential decay described by the equation C¼5.89 e
 1.51tþ3.36
e
 0.1tþ0.120 e
 0.0084t. This model gives three half-lives of 0.46,
6.91 and 82.5h and elimination rate constants of 1.51, 0.1 and
0.0084h
 1, respectively (Table 1A).
A noncompartmental analysis using statistical moments gives a
better overall view of the pharmacokinetics as it compensates for
individual data being collected from a number of animals.
For the noncompartmental approach, the calculation method
was as follows.
(1) The plasma concentration of m-THPC at time zero (C0) was
estimated by extrapolation of the log concentration vs time
graph back to zero.
(2) The slope of the log linear (elimination) phase (k0
N ) was
estimated between 72 and 168h.
(3) The area under the concentration vs time graph (AUC) was
calculated from time zero to the last time point (T(last)) by the
trapezoidal rule and from T(last) to infinity as Area¼C(last)/
k0, where C(last) is the plasma concentration at the last time
point (168h).
(4) The area under the (concentration time) vs time curve
(moment curve, AUMC) was calculated from time zero to
T(last) by the trapezoidal rule and T(last) to infinity as
Area¼C(last)/(k0 )
2.
(5) Plasma clearance CL¼DOSE/AUC.
(6) Mean residence time MRT¼AUMC/AUC.
(7) Volume of distribution Vd¼CL MRT.
(8) Half-life T1/2¼MRT ln(2).
(9) Elimination rate constant Kel ¼1/MRT.
Table 1B shows the noncompartmental pharmacokinetic para-
meters obtained. This approach gives an elimination rate constant
of 0.03h
 1 and a biological half-life of 22.6h.
From the compartmental analysis, the initial volume of
distribution of the central compartment, calculated from the
initial plasma concentration (Dose/C0), was estimated to be
32.0mlkg
 1. The phases of the three compartments, however,
have volumes of distribution of 50.9, 89.3 and 2500mlkg
 1
(Table 1A) while noncompartmental analysis shows an average Vd
of 172mlkg
 1. These values suggest that some tissues preferen-
tially accumulate m-THPC (i.e. the volumes are so much larger
than the blood volume).
Tissue distribution of m-THPC in the BDIX rat
All tissues studied showed an accumulation of m-THPC with the
highly perfused tissues such as liver and kidney accumulating
higher levels of m-THPC than the peripheral tissues like skin and
muscle (Figure 2). The contribution of the blood levels of m-THPC
to the levels in the different tissues can be estimated if it is
assumed that the initial tissue value (o2min) was due solely to the
blood content and this contribution decreased in the same manner
as the plasma pharmacokinetics. Therefore, the m-THPC levels are
also shown after subtraction of the m-THPC present in the tissue
due its blood content. This mainly affected the tissues with high
blood volume and which showed peak concentrations at the first
time point (o2min) (Table 2).
Tumour concentration rises quickly in the first 24h with the
concentration remaining above 0.4mgg
 1 from 6 to 48h
(Figure 2A). The maximum level in the tumour is 0.5470.15mgg
 1
at 24h and after 48h the concentration in the tumour declines
quickly. The liver has an extremely high initial concentration of m-
THPC and it accumulates approximately 30 times the original dose
of 0.3mgkg
 1. This suggests some type of significant uptake
mechanism for m-THPC consistent with its role as a detoxification
organ. The kidney and heart have similar levels of m-THPC,
approximately twice the original dose. The sensitiser accumulates
rapidly in the first 2h slowing to a peak at 24–48h similar to the
pattern of uptake by the liver. The muscle and skin accumulate the
least amount of m-THPC.
The elimination rates from the tissues (Table 3) were calculated
from the log concentration vs time graphs using the last three data
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Figure 1 Semilog plot of the pharmacokinetics of
14C m-THPC in the
plasma of the BDIX rat injected with 0.3mgkg
 1 (data points show the
mean7s.d., n¼3).
Table 1 Pharmacokinetic parameters calculated using (A) the exponen-
tial equations of the three compartment model equation of 5.89
e
 1.51t+3.36 e
 0.1t+0.120 e
 0.0084t (A e
 at+Be
 bt+Ce
 gt), and (B) the
noncompartmental method (dose¼0.3mgkg
 1m-THPC)
Pharmacokinetic parameter Result
(A)
Initial concentration (C0) 9.37mgml
 1
Initial volume of distribution (Vd) 32.0mlkg
 1
Vd of first compartment 50.9mlkg
 1
Vd of second compartment 89.3mlkg
 1
Vd of third compartment 2500mlkg
 1
t1/2 of first compartment 0.46h
t1/2 of second compartment 6.91h
t1/2 of third compartment 82.5h
(B)
Mean residence time (MRT) 32.5h
Elimination constant (Kel) 0.0307h
 1
Half-life (t1/2) 22.6h
Plasma clearance 5.29mlkg
 1h
 1
Volume of distribution (Vd) 172mlkg
 1
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spoints. These were very similar in some tissues, suggesting they are
part of one compartment for elimination. The terminal elimination
rates of the tumour and liver are similar to that of the plasma,
indicating that m-THPC diffusing out of these tissues in the later
stages of the experiment was immediately eliminated. The kidney
and the heart had a similar elimination profile of m-THPC but with
a longer half-life, suggesting another possible compartment in the
model (Table 3). The muscle and skin showed comparable shaped
kinetic profiles, although the m-THPC levels in the muscle were
half that of the skin. Once the m-THPC had entered these tissues it
did not enter an elimination phase, as the log linear portion of the
log concentration vs time plot is almost constant from 72–168h
(data not shown). The slow elimination is probably due to slow
diffusion out of these tissues. This indicates another possibly
longer half-life for m-THPC, which was not encountered in the
plasma pharmacokinetics during this time course.
A high tumour to normal tissue ratio for a photosensitiser is
particularly important in PDT to ensure maximum effect in the
tumour with minimal normal tissue damage. There was no general
trend for the tissues although some tissues can be grouped
together with the highly perfused tissues, such as the liver, having
low ratios over the entire time course (Table 4). Tumour to tissue
ratios are high for muscle and skin peaking at 10.4 and 4.1,
respectively. These ratios occur at earlier time points than peak
tumour concentrations (24h) although the ratio remains high (i.e.
above 1) for most of the time course.
Photodynamic therapy efficacy of m-THPC in the BDIX rat
Tumour growth delay of treated tumours was calculated by
comparison with the rate of growth of tumours in control animals.
Light only and drug only controls showed no deviation from
control animals. The pattern of tumour growth delay over the time
course was similar for both a 652nm diode laser (Figure 3) and a
652nm Copper Vapour pumped dye laser (data not shown) with
no significant difference between the two sources. After most
treatments, there was an immediate increase in tumour diameter
that regressed after approximately 24h. This oedema is a short-
lived inflammatory response due more to the insertion of the fibre
than PDT and has also been observed with other photosensitisers
in this model (Cruse-Sawyer et al, 1998).
Photodynamic therapy efficacy peaked at 2–4h postadministra-
tion with an apparent second peak at 24h. There was no significant
difference between treatments at 0, 6, 48, 72 and 96h for the diode
laser (P40.05). However, the 2h interval was significantly
different to all time points except 4 and 24h (Po0.05). Hence,
there were two peaks in tumour growth delay, an early peak
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Figure 2 Concentration of m-THPC in selected tissues of the BDIX rat
at different times after an intravenous injection of
14C m-THPC
(0.3mgkg
 1). Data corrected for blood content of the tissue (–––). (A)
LSBD1 tumour, (B) liver, (C) kidney, (D) heart, (E) muscle and (F) skin.
(data points show the mean7s.d., n¼3).
Table 2 Time and concentration of maximal levels of
14C m-THPC in
each tissue of the BDIX rat (data represent mean7s.d. (n¼3))
Tissue Peak (h) Concentration (lgg
 1)
Tumour 24 0.5470.15
Liver 2 9.7473.01
Skin 96 0.2270.02
Muscle 24 0.0770.02
Plasma o5min 9.3770.19
Table 3 Elimination rate constants and half-lives of the terminal phase of
elimination in several tissues of the BDIX rat injected with 0.3mgkg
 11 4C
m-THPC
Tissue Elimination rate
constant ( 10
3h
 1)
Half-life (h)
Plasma 8.40 82.5
Tumour 8.46 81.9
Liver 7.13 97.3
Kidney 3.52 196.7
Heart 3.61 191.9
Table 4 Ratio of
14C m-THPC concentration in the LSBD1 tumour
compared to normal tissue (dose: 0.3mgkg
 11 4C m-THPC)
Time (h) Muscle Skin Liver
2 7.40 2.44 0.03
4 9.39 4.06 0.04
6 10.36 2.43 0.05
24 7.57 3.09 0.18
72 4.04 1.35 0.28
96 2.97 0.77 0.22
Concentrations used for calculations were not corrected for blood content of the
tissue.
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intervals that caused significant tumour growth delay, there were
periods of tumour stasis that lasted up to 5 days after the initial
regression; this was then followed by a period of increased growth
at a slower rate than the controls (data not shown).
Photodynamic therapy treatment of isolated LSDB1
tumour cells
The LSBD1 tumours were removed 2 and 24h after injection of
0.3mgkg
 1 m-THPC. The tumour cells were isolated, and treated
in vitro to investigate the extent of direct cell kill compared to
indirect cell damage caused by vascular or stromal elements. The
amount of m-THPC present in the cell should not change during
the 4h of cell attachment (after isolation), as m-THPC is known to
remain in cells even if serum is present extracellularly (Ball et al,
1999). Figure 4 shows that the PDT effect is greater in the tumour
cells extracted 24h after injection than those extracted after 2h.
The phototoxicity was dependent on light dose, the higher light
doses caused more cell damage in both experiments. At every light
dose, cell survival was significantly lower for the cells extracted
after 24h (Po0.05).
DISCUSSION
For any single PDT treatment, there are a variety of important
factors that need to be optimised. These range from the choice of
photosensitiser and administration dose, to the time interval
before treatment, as well as considering any one of the light dose
parameters. Preclinical results indicate that the efficacy of m-
THPC is related to both the drug dose and the interval between
administration and illumination (Ris et al, 1993a,b). However, the
efficacy is also complicated by many in vivo interactions, such as
aggregation and protein binding (Glanzmann et al, 1998;
Hopkinson et al, 1999). This study aims to correlate m-THPC
pharmacokinetics with PDT efficacy and the mechanism of PDT
damage. Radiolabelled (
14C) m-THPC was used in this study to
avoid the problems encountered with noninvasive induced
fluorescence determination (Lin, 1990).
The plasma pharmacokinetics of m-THPC in BDIX rats best
fitted three exponential decays and considering the influence of
each component a general prediction can be made. The three
phases of elimination represent a rapid distribution phase, a
second phase that consists of mainly elimination with slight
redistribution, while the final phase shows elimination from other
tissues. There is also a high initial retention in the vasculature that
is confirmed by initial volume of the distribution (32.0mlkg
 1),
which is small compared to the blood volume of a rat (50–
70mlkg
 1). m-Tetra (hydrophenyl)chlorin may be initially re-
tained in the vascular system, possibly due to protein binding or
precipitation (Clark and Smith, 1986). This is consistent with
plasma binding studies with m-THPC that shows an unusual initial
protein-binding pattern for a hydrophobic photosensitiser (Hop-
kinson et al, 1999).
A similar study using
14C-labelled m-THPC in mice (Cramers
et al, 2003) has shown that the decrease in photosensitiser levels in
plasma can be described by a second-order decay with half-lives of
1.3 and 20.9h. Although these half-lives cannot be directly
compared to the three compartment analysis for the rat data, they
do show a similar rapid initial distribution phase and a much
longer elimination phase. In the Syrian hamster, a much longer
plasma half-life (2–3 days) has been demonstrated. This is similar
to the terminal half-life of 82.5h in the BDIX rat. It must be pointed
out however that the early plasma pharmacokinetic data is likely to
be a reflection of the plasma lipoprotein profile of the particular
species being studied. Rats and mice have very little low-density
lipoprotein (LDL), whereas the profile of the hamster is similar to
that of humans although the composition of the individual
lipoproteins differs slightly (Goulinet and Chapman, 1993).
The present study was too short to show the terminal
elimination half-life from the peripheral tissues as determined by
the log concentration plots for skin and muscle. However,
Whelpton et al (1995) showed a terminal half-life of approximately
10 days in mice as measured by excretion rates.
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Figure 3 Tumour growth delay of the LSBD1 tumour following
interstitial treatment at different times after intravenous injection of
0.3mgkg
 1 m-THPC in the BDIX rat. A light dose of 50J (100mW) was
delivered via a 200mm optical fibre with a 0.5cm diffusing tip. (data points
show the mean7s.d., nX3).
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Figure 4 Phototoxicity of cells isolated from a LSBD1 tumour after
intravenous injection of m-THPC (0.3mgkg
 1) followed by in vitro light
treatment with xenon arc lamp (5–40mWcm
 2). Cells isolated after 2h
(—) and 24h (–––) (data points show the mean7s.d., n¼3).
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m-THPC in the BDIX rat is 22.6h. This compares with 80h for a
Photofrin equivalent in the same model (Vernon et al, 1995). This
shows that the clearance of m-THPC is faster than that of
Photofrin. Similar pharmacokinetic analyses in humans have
determined half-lives as 452h for Photofrin (Brown et al, 1992)
and 30h for m-THPC (Glanzmann et al, 1998).
The plasma pharmacokinetics of m-THPC in humans is unusual
for an intravenous dose, and several studies show a secondary
peak at 24h (Ronn et al, 1996; Glanzmann et al, 1998). Ronn et al
(1996) showed a secondary peak at 4–6h in rabbit plasma.
Although, there is no secondary peak shown in the rat data
presented here, the levels at 2h are still high and it is possible that
this phenomenon is much shorter in a rat, hence a peak might
be present between 0 and 2h in this study. There is some
evidence from the density gradient ultracentrifugation analysis
that m-THPC is initially highly aggregated in rat plasma
but disaggregates and redistributes to lipoproteins with time
(Hopkinson et al, 1999).
High levels of m-THPC in the tumour would suggest a good PDT
response, although the intracellular localisation of the photo-
sensitiser is critically important. The tumour concentration rises
quickly in the first 6h with its concentration staying above
0.4mgg
 1 from 6 to 48h. Low tumour concentration at the later
time points (48–168h) could be due to the concentration of m-
THPC being diluted due to the rapid growth of the tumour. The
LSBD1 tumour in this model has a doubling time of approximately
1.5–2 days. These kinetic data are similar to those seen in other
tumours and animal models. Whelpton et al (1995) showed that
tumour concentrations of m-THPC in a mouse model peaked at
24h at 1.4970.25mgg
 1 and Peng et al (1995) demonstrated, in
another mouse tumour, a peak at 48h of approximately 2mgg
 1.
Cramers et al (2003) found similar levels in a human mesothelioma
xenograft in BALBlc mice.
The level of m-THPC in other tissues is also important in PDT to
predict the possible extent of normal tissue damage. In this study
the liver has an extremely high concentration of m-THPC,
reflecting its role in the elimination of m-THPC (Alian et al,
1994; Whelpton et al, 1996). The m-THPC initially disappears
rapidly from the liver unlike Photofrin or our own equivalent
(PHP), which in the same animal and tumour model stays at a high
concentration for several days (Stribbling, 1991). The much slower
elimination phase of m-THPC (Table 3) is similar to that of
plasma. Hence the photosensitisers have different mechanisms of
sequestration or redistribution and removal from the liver,
possibly conferring an advantage for m-THPC. One postulation
is that m-THPC could disaggregate and redistribute to lipoproteins
in the liver before further distribution to other tissues. The kidney,
heart and lung all have a relatively high concentration of m-THPC.
In the case of lung tissue, the peak concentration of m-THPC
reached a maximum of 2mgg
 1 and the elimination profile was
almost identical to that of the tumour (data not shown). This
follows observations that tissues of the reticuloendothelium system
accumulate high concentrations of photosensitisers (Gomer and
Dougherty, 1979; Alian et al, 1994; Peng et al, 1995). The skin and
muscle accumulated m-THPC more slowly and appear to peak at
24h and 96h, respectively (Figure 2). The elimination phase did
not occur in the time course of this study and a half-life could not
be determined. The levels in the skin remained at peak
concentrations throughout the remaining time of the study. This
is in agreement with studies in the mouse (Cramers et al, 2003).
This m-THPC could give rise to prolonged skin sensitivity
although it may be rapidly photobleached, due to the sharp
absorption bands, avoiding the photosensitivity (Ma et al, 1994).
Studies in the hamster (Blant et al, 2002) have shown that levels of
m-THPC in striated muscle are very low, increasing slightly over
200h. This was shown to be quite different from smooth muscle,
which accumulated relatively higher levels and peaked at about
36h. The data for striated muscle in the BDIX rat presented here
are consistent with the data for the hamster model.
PDT efficacy was also determined over the same drug light
intervals for direct correlation with tumour sensitiser levels. The
major feature of the PDT efficacy time course (drug to light time
interval) was that there were two peaks of tumour growth delay (2
and 24h). In studies in human mesothelioma xenografts, a similar
early peak of PDT effect was seen at 3h mice (Cramers et al, 2003).
No second peak in efficacy could be seen in this study although the
presence of one could not be ruled out. One contributing factor to
this difference may be related to the doubling time of the tumours.
The LSBD1 tumour has a doubling time of about 2 days, whereas
that of the mesothelioma xenograft was 15 days (Cramers et al,
2003); a greater rate of cell division giving rise to a faster cellular
uptake.
The pattern of efficacy does not follow the pattern of m-THPC
concentration in the tumour. Significantly different drug
concentrations in the tumour (0.2970.03mgg
 1 at 2h and
0.5470.15mgg
 1 at 24h) produce similar tumour growth delay
(Figure 3). Similarly, PDT efficacy does not parallel the m-THPC
concentration in the plasma as has been shown for BPDMA (Lin
et al, 1998) and m-THPC in the mouse (Cramers et al, 2003). This
would not explain the peak of activity at 24h as plasma levels of m-
THPC are much lower at 24h than at 2h. Finally, a specific
localisation has been postulated as a prerequisite for optimum
photosensitisation, suggesting that photosensitisers may have
different PDT mechanisms at different time points (Star et al,
1986; Henderson and Bellnier, 1989).
The mechanisms involved in the initiation of tumour destruc-
tion by PDT are difficult to distinguish and are thought to be
dependent on the localisation of the photosensitiser due to the
small diffusion distance of the reactive oxygen species (Peng et al,
1996). Intracellularly localised photosensitisers produce more
direct cell kill in comparison to those photosensitisers accumulat-
ing in the interstitial space, which cause more vascular and stromal
effects. The mode of action of m-THPC in the LSBD1 tumour at 2
and 24h was examined by assessing tumour cell survival after
administration of m-THPC in vivo, followed by cell isolation and
light exposure in vitro.
The cells extracted 24h after injection of m-THPC showed a
significantly higher PDT effect than those extracted after 2h,
whereas in vivo the effects are relatively similar, indicating either
more m-THPC present in the cell or a specific localisation within
the cell. Localisation studies of m-THPC have shown strong
fluorescence in the vasculature walls at 1h, while at 24h m-THPC
is still present in the vasculature but also localised intracellularly
(Peng et al, 1995, 1996). Similar vascular deposition has been
determined in the Syrian Hamster (Blant et al, 2002). This suggests
that the effect at 2h, probably caused by m-THPC present in the
plasma or interstitial space, is due more to damage of the
vasculature leading to deprivation of oxygen and nutrients causing
tumour cell death and loss of tumour structure (Denekamp, 1992).
Menezes Da Silva and Newman (1995) reported that the vascular
effect of m-THPC was unlikely to be a direct effect on the
vasculature but accumulation at alternative sites that have an
indirect effect on blood capillaries. However, at 24h m-THPC has
accumulated intracellularly and has a more direct effect.
CONCLUSION
The biological half-life of m-THPC in the BDIX rat model, as
determined using a noncompartmental pharmacokinetic ap-
proach, is 22.6h. This is much lower than that for a Photofrin
equivalent that has a half-life of 80h in the same model. The
photodynamic effect of m-THPC in the BDIX rat fibrosarcoma
shows two peaks of activity in the 96h study. Ex-vivo investiga-
tions suggest that the early effect at 2h is probably due to a
PDT effects of m-THPC
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tions, with a more direct cell kill mechanism being involved at
24h. This latter peak correlated with maximum tumour concen-
trations of m-THPC.
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